# Ph I Oral Topotecan and Temozolomide for Patients With Malignant Gliomas

> **NCT00610571** · PHASE1 · COMPLETED · sponsor: **Katy Peters** · enrollment: 62 (actual)

## Conditions studied

- Glioblastoma
- Gliosarcoma
- Anaplastic Astrocytoma

## Interventions

- **DRUG:** Oral Topotecan and Temodar

## Key facts

- **NCT ID:** NCT00610571
- **Lead sponsor:** Katy Peters
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-04
- **Primary completion:** 2009-09
- **Final completion:** 2012-04
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2013-10-25

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00610571

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00610571, "Ph I Oral Topotecan and Temozolomide for Patients With Malignant Gliomas". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00610571. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*